OncoMatch/Clinical Trials/NCT05691517
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
Is NCT05691517 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies pH Low Insertion Peptide-exatecan Conjugate CBX-12 for advanced malignant solid neoplasm.
Treatment: pH Low Insertion Peptide-exatecan Conjugate CBX-12 — This phase I trial studies how well CBX-12 works in treating patients with solid tumors that have spread from where they first started (primary site) to started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or other places in the body (metastatic). CBX-12 works by binding to a protein called TOP1 that is present inside the cells. This allows CBX-12 to kill the cancer cells by damaging their DNA, resulting in cancer cell death. This trial is being done to find out if this approach is better or worse than the usual approach for advanced cancers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Absolute neutrophil count >= 1,500/mcL; Hemoglobin >= 9 g/L; Platelets >= 100,000/mcL
Kidney function
Creatinine <= 1.5 x institutional ULN or creatinine clearance >= 60 ml/min (Cockcroft-Gault)
Liver function
Total bilirubin <= 1.5 x institutional ULN (Gilbert disease up to 3 mg/dl allowed); AST/ALT <= 3 x ULN (<= 5 x ULN with liver involvement)
Cardiac function
NYHA Functional Classification class 2B or better
Absolute neutrophil count >= 1,500/mcL; Hemoglobin >= 9 g/L; Platelets >= 100,000/mcL; Total bilirubin <= 1.5 x institutional ULN (Gilbert disease up to 3 mg/dl allowed); AST/ALT <= 3 x ULN (<= 5 x ULN with liver involvement); Creatinine <= 1.5 x institutional ULN or creatinine clearance >= 60 ml/min (Cockcroft-Gault); NYHA Functional Classification class 2B or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- National Cancer Institute Developmental Therapeutics Clinic · Bethesda, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify